Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Core Viewpoint - Onconetix, Inc. has announced a licensing agreement with Immunovia AB for the production of antibodies related to pancreatic cancer diagnostics, which is expected to enhance the early detection of pancreatic cancer through the PancreaSure test [1][2]. Group 1: Licensing Agreement Details - Proteomedix AG, a subsidiary of Onconetix, will provide Immunovia with master cells necessary for producing antibodies for three of the five biomarkers in the PancreaSure test [2]. - The agreement includes a license for key intellectual property related to the manufacturing of reagents for measuring these biomarkers, allowing Immunovia to purchase reagents directly from Proteomedix [2]. - Immunovia will pay a total of $700,000 to Proteomedix in 2025 and 2026, along with a 3% royalty on net sales of PancreaSure and other products using the licensed intellectual property from 2026 to 2032 [3]. Group 2: Company Focus and Products - Onconetix is focused on innovative solutions for men's health and oncology, with a particular emphasis on the early detection of prostate cancer through its Proclarix® test [4][5]. - Proclarix® is CE-certified and indicated for prostate cancer diagnosis in patients with specific clinical conditions, demonstrating reliability in detecting clinically significant prostate cancer [6].